Abstract: A rotating shaft assembly and an electronic device, where the rotating shaft assembly includes a panel and a rotatable support mechanism. The rotatable support mechanism includes a swing arm, a fixed structure, a limit part, and a support structure. The support structure is provided with a mounting plane, and the panel is fastened to the mounting plane; a first limit portion is formed on the swing arm; and the limit part is connected to the support structure, and a second limit portion is formed on the limit part. When the screen is in a folded state, the limit part is separated from the swing arm. When the screen is in an unfolded state, the second limit portion of the limit part can abut against the first limit portion of the swing arm, thereby implementing mutual constraint between the swing arm and the support structure.

Abstract: This application relates to a rotating assembly, a foldable mechanism, and a foldable terminal, and relates to the field of terminal technologies. The rotating assembly includes a base, a rotating shaft, and a swing arm, where the base is provided with a rotating shaft through-hole and an arc-shaped first slideway, the first slideway and the rotating shaft through-hole communicate with each other, and axes thereof are parallel to each other; the rotating shaft is provided with an arc-shaped second slideway, an axis of the rotating shaft is parallel to an axis of the second slideway, the second slideway runs through the rotating shaft, and a radius of the second slideway is equal to that of the first slideway; the rotating shaft is located in the rotating shaft through-hole, the first slideway and the second slideway can be connected to each other to form a continuous slideway, and the swing arm is located in the continuous slideway and can slide in the continuous slideway.

Abstract: The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

Abstract: The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

Abstract: The present invention relates to the crystal form of imidazolone type compounds, and a preparation method, pharmaceutical composition and use thereof, and falls within the field of pharmaceutical compound crystals. The crystal form provided by the present invention has a good stability, comprising good stability under the three extreme conditions of high temperature, high humidity and strong illumination, and can also maintain a good stability during the tablet compressing process. The crystal form provided by the present invention has good absorption and metabolism properties in vivo, comprising the drug concentration of blood, the drug concentration-time curve AUC, the half-life period, etc. In addition, the dissolving rate of the crystal form of the present invention is improved, wherein same is beneficial for the applications thereof in preparations.

Abstract: The present invention relates to the crystal form of imidazolone type compounds, and a preparation method, pharmaceutical composition and use thereof, and falls within the field of pharmaceutical compound crystals. The crystal form provided by the present invention has a good stability, comprising good stability under the three extreme conditions of high temperature, high humidity and strong illumination, and can also maintain a good stability during the tablet compressing process. The crystal form provided by the present invention has good absorption and metabolism properties in vivo, comprising the drug concentration of blood, the drug concentration-time curve AUC, the half-life period, etc. In addition, the dissolving rate of the crystal form of the present invention is improved, wherein same is beneficial for the applications thereof in preparations.

Abstract: This application relates to imidazolone compounds, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.

Abstract: This application relates to imidazolone compounds, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.